Golph3在上皮性卵巢癌中的表达及临床意义

发布时间：2018-05-05 22:51

本文选题：卵巢癌 + GOLPH3表达　；参考：《大连医科大学》2014年硕士论文

【摘要】：背和目的:高尔基体磷蛋白3(Golgi phosphoprotein3, GOLPH3)是于2009年6月才发现的癌基因，研究表明这种基因能促进肿瘤细胞的生长、分化和增殖，机制可能是调节哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin,mTOR)信号通路，肿瘤细胞对雷帕霉素的敏感性也受此基因调节。现有的研究提示Golph3在神经胶质瘤，前列腺癌,乳腺癌等均有明显的表达，目前国内外关于GOLPH3在肿瘤中表达的研究还比较少。本研究通过检测GOLPH3在上皮性卵巢癌及正常卵巢组织中的表达，，探讨GOLPH3,与上皮性卵巢癌临床病理指标的关系以及其是否能成为卵巢癌分子靶向治疗又一新靶点。方法：回顾分析31例上皮性卵巢癌患者及31例子宫良性肿瘤行卵巢切除患者的临床及病理资料。采用免疫组化的方法(SP法)检测31例上皮性卵巢癌组织、31例正常卵巢组织中GOLPH3的表达;采用卡方检验及秩和检验等方法分GOLPH3表达与上皮性卵巢癌临床病理因素的关系。结果：1,GOLPH3免疫染色定位于细胞质中主要有两个模式，一是凝聚成较大的颗粒分布在细胞核周围，二是以细颗粒的形式分散在细胞质中,GOLPH3在上皮性卵巢癌中的表达与在正常卵巢组织中表达相比有显著增高，差异具有统计学意义(x2=47.032P0.05)。 2，GOLPH3在上皮性卵巢癌不同分期、不同分级分组间的阳性表达强度差异也同样具有统计学意义(P0.05)，且其阳性表达随分期、分级的增高而增强(P0.05),但在年龄、病理组织类型分组中的表达差异没有统计学意义(p0.05)。结论:1, GOLPH3在上皮性卵巢癌中的阳性表达率明显高于正常卵巢组织，提示上皮性卵巢癌的发生与GOLPH3的异常表达之间存在密切相关性。 2,随着肿瘤的分期、分级的增高，GOLPH3在上皮性卵巢癌中的阳性表达也增强，从而提示GOLPH3表达强度与上皮性卵巢癌恶性程度及肿瘤进展程度成正向相关，GOLPH3也许能成为辅助判断上皮性卵巢癌预后好坏的标志物,需要进一步研究。 3, GOLPH3在上皮性卵巢癌组织中高表达现象，提示GOLPH3很可能成为卵巢癌靶向治疗的一个有利靶点
[Abstract]:Back and objective: Golgi phosphoprotein 3 (GOLPH3) is a oncogene discovered in June 2009, which has been shown to promote the growth, differentiation and proliferation of tumor cells. The mechanism may be the regulation of mammalian rapamycin target protein mammalian target of rapamycin mTOR. the sensitivity of tumor cells to rapamycin is also regulated by this gene. The existing studies suggest that Golph3 is expressed in gliomas, prostate cancer, breast cancer and so on. At present, there are few studies on the expression of GOLPH3 in tumors at home and abroad. In this study, we examined the expression of GOLPH3 in epithelial ovarian carcinoma and normal ovarian tissues, and explored the relationship between GOLPH3 and clinicopathological parameters of epithelial ovarian cancer and whether it could be a new target for molecular targeted therapy of ovarian cancer. Methods: the clinical and pathological data of 31 patients with epithelial ovarian cancer and 31 patients with benign uterine tumor were retrospectively analyzed. Immunohistochemical method was used to detect the expression of GOLPH3 in 31 normal ovarian tissues from 31 cases of epithelial ovarian carcinoma and the relationship between GOLPH3 expression and clinicopathological factors of epithelial ovarian carcinoma was analyzed by chi-square test and rank sum test. Results there were two main patterns in the cytoplasm of the cytoplasm, one was the aggregation of larger particles around the nucleus, and the other was the distribution of large particles around the nucleus. The expression of GOLPH3 in epithelial ovarian carcinoma was significantly higher than that in normal ovarian tissue, and the difference was statistically significant. 2the positive expression intensity of GOLPH3 in different stages of epithelial ovarian cancer was also significantly different among different grading groups, and the positive expression of GOLPH3 increased with the stage and grade, but at the age, the positive expression of GOLPH3 was increased with the stage and grade of ovarian carcinoma, but at the age, the positive expression of GOLPH3 was increased with the stage and grade of epithelial ovarian cancer. There was no significant difference in the expression of P0. 05 in the histopathologic groups. Conclusion the positive expression rate of GOLPH3 in epithelial ovarian carcinoma is significantly higher than that in normal ovarian tissue, suggesting that there is a close correlation between the occurrence of epithelial ovarian cancer and abnormal expression of GOLPH3. 2. With the stage of the tumor, the positive expression of GOLPH3 in epithelial ovarian cancer was also increased with the increase of grade. The results suggest that the positive correlation between the expression of GOLPH3 and the malignant degree and progression of epithelial ovarian cancer may be a marker of the prognosis of epithelial ovarian cancer, which needs further study. 3. The overexpression of GOLPH3 in epithelial ovarian cancer tissues suggests that GOLPH3 may be a favorable target for the targeted therapy of ovarian cancer.
【学位授予单位】：大连医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.31

【相似文献】